about
TNF-alpha inhibitors for juvenile idiopathic arthritisIntravenous immunoglobulin for juvenile idiopathic arthritisClinical outcome measures in juvenile idiopathic arthritisThe clinical effectiveness of intra-articular corticosteroids for arthritis of the lower limb in juvenile idiopathic arthritis: a systematic reviewJuvenile Idiopathic Arthritis: Diagnosis and TreatmentTechnical tips to perform safe and effective ultrasound guided steroid joint injections in children.Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis.Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.Impact of a telenursing service on satisfaction and health outcomes of children with inflammatory rheumatic diseases and their families: a crossover randomized trial study protocol.Temporomandibular condylar alterations in juvenile idiopathic arthritis most common in longitudinally severe disease despite medical treatmentHLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia.Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond.Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritisPrediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.Systemic arthritis in children: a review of clinical presentation and treatmentIL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors.Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.Treatment preferences in juvenile idiopathic arthritis - a comparative analysis in two health care systemsMutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis.Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study.Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis.BOLD MRI at 1.5 Tesla in juvenile idiopathic arthritis: preliminary experience.Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritisAbatacept in difficult-to-treat juvenile idiopathic arthritis.Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: Safety, efficacy, and features affecting outcome. A comprehensive review of the literature.Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan.Intra-articular corticosteroid therapy for juvenile idiopathic arthritis: report of an experiential cohort and literature review.Ultrasound-guided steroid tendon sheath injections in juvenile idiopathic arthritis: a 10-year single-center retrospective study.Biologics in children's autoimmune disorders: efficacy and safety.Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment.Advances and challenges in imaging in juvenile idiopathic arthritis.Juvenile idiopathic arthritis in the new world of biologics.Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.Pharmacology of intra-articular triamcinolone.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.
P2860
Q24234429-B93BB467-C40A-4776-98AB-B4C21BFAE71BQ24244815-B763476F-5713-411C-BBB4-A2B1CFFD4041Q26752701-17BBEAA6-7D9B-42F4-A8AD-1E757A118645Q26825309-C21E5905-F29B-4038-94C0-45D063D5D016Q28079246-053EAD64-0FC6-4D72-BEFF-ECF5129AAD61Q30417114-9833F64D-AF20-4F5F-86F2-9710C3FBD407Q33575269-92837801-3E98-4C95-93F4-42BB708447E7Q33659233-A29BF913-62B7-4A95-88B6-4B8279AD6F89Q33794402-2602F665-4FEC-4C44-AD16-1E71833EB5ACQ34227357-55496733-0BC0-4F3F-8C5D-D245FCEC532CQ34244086-1E7D3A22-DD54-4F9E-8AB7-EFAC08543120Q34363306-12EF596F-69E0-4CC5-88CD-4B37D12B606FQ34885098-C957CCC9-D25D-49FD-A350-0654650B6A45Q35147847-11BE1BB4-2CEB-49AC-95C8-0246BA6B9465Q35659928-2C772F5D-6C3D-4F46-9F99-9A1D05F192BCQ35954465-52BA1C2B-F834-48DF-AF07-0F4E4F36C255Q36204110-434AFB2B-F2CA-4C58-B86D-935DF04C0845Q36420780-7CC36DE3-6543-47D1-8D94-1B3F1D8DAD64Q36614214-8906716B-E40D-4B48-8EFB-A883C6FAF1B3Q36634766-11C114D1-4018-4922-A0DD-E6D0D84EA094Q36725336-283B6D21-C738-494F-8FFA-C3693CE704ECQ36725341-89CA3FB3-43EE-44A0-B3CE-48CAB7AC2D61Q36844927-C5E55A44-5FC4-4AB1-B5C8-8471E8DB2E9BQ37207120-A87FF9BB-CF1D-489C-A980-09F37C6ED059Q37307846-1BF8297A-DF13-4EDF-8F98-BEB3B1AC9824Q37358118-4E4AA82B-6ABE-41F4-8C0A-C066378059B5Q37462544-DDD9656B-2212-4539-850D-69A06CA26E6DQ37678277-0087B485-B63A-422D-87BE-4F65D06902E7Q37692255-25148B4A-1E49-479A-8FB7-B1A75450141FQ37747783-E0AF2609-6D56-4338-97ED-680AB06A74F5Q37765830-C204215C-BED3-449E-821A-0C10A0CE623DQ37845682-3BBB8CDD-4564-42A0-9A5C-71FDBF65D1CBQ37866288-69B2F8A2-CE27-4CA6-9042-38E6A269E7D0Q37930506-65C74A8E-370C-41A8-A39D-00235737E66EQ37997306-C3398E49-7F7D-47C1-80EF-66C45AC7986AQ38104461-04DE63BA-B649-4B1C-B2C5-73003A9D744CQ38155126-CCFE12BD-6E8F-485D-AC21-DA9A2FC4D658Q38176004-7B8C9994-035A-426A-A755-8D5FEE6BB823Q38211488-75BA6B47-2310-4F0F-9EE6-4C9DCE277A34Q38214382-EF4F4ACF-2BB7-46C9-88B4-A1246FC41F4B
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Medical treatment of juvenile idiopathic arthritis.
@ast
Medical treatment of juvenile idiopathic arthritis.
@en
Medical treatment of juvenile idiopathic arthritis.
@nl
type
label
Medical treatment of juvenile idiopathic arthritis.
@ast
Medical treatment of juvenile idiopathic arthritis.
@en
Medical treatment of juvenile idiopathic arthritis.
@nl
prefLabel
Medical treatment of juvenile idiopathic arthritis.
@ast
Medical treatment of juvenile idiopathic arthritis.
@en
Medical treatment of juvenile idiopathic arthritis.
@nl
P356
P1476
Medical treatment of juvenile idiopathic arthritis.
@en
P2093
Philip J Hashkes
Ronald M Laxer
P304
P356
10.1001/JAMA.294.13.1671
P407
P577
2005-10-01T00:00:00Z